Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03832361
Title Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Alessandro Santin

endometrial adenocarcinoma

endometrial serous adenocarcinoma

uterine carcinosarcoma


Mirvetuximab Soravtansine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.